Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
ICM
AddedMar 20, 2024
UpdatedJun 18, 2026
ICM

ICM

Developing gene therapy for osteoarthritis and age-related macular disease.

HQ
Kaleponi, MD, US
Founded
1954
Overview
Compare
Fundraising
Employees

ICM is dedicated to developing gene therapy solutions targeting osteoarthritis and age-related macular disease. The company focuses on innovative treatments to address these chronic conditions, aiming to improve the quality of life for patients suffering from these ailments.

ICM has made significant strides in gene therapy research, contributing to advancements in medical treatments for osteoarthritis and age-related macular disease. Their work has the potential to revolutionize how these conditions are managed, offering new hope to patients worldwide.

ICM - Similar Companies

Oculogenex logo

Oculogenex

oculogenex.com

Genascence logo

Genascence

genascence.com

Imagen Biotech logo

Imagen Biotech

EyeCyte logo

EyeCyte

eyecyte.com

Icvrx logo

Icvrx

Iecure logo

Iecure

iecure.com

ImmunoVec logo

ImmunoVec

immunovec.com

International Stem Cell logo

International Stem Cell

Ikaria logo

Ikaria

Iscience Surgical logo

Iscience Surgical

EyeIC logo

EyeIC

Sarcio logo

Sarcio

sarcioinc.com

i-Lumen Scientific logo

i-Lumen Scientific

i-lumen.com

Geneicd logo

Geneicd

Hemera Biosciences logo

Hemera Biosciences

ICM - Quick Facts

Who are ICM's competitors?

Companies similar to ICM include Oculogenex, Genascence, Imagen Biotech and EyeCyte.

When was ICM founded?

ICM was founded in 1954.

Where is ICM's headquarters located?

ICM's headquarters is located in Kaleponi, MD, US.

When was ICM's last funding round?

ICM's most recent funding round was for $2B (USD) in June 2017.

How much has ICM raised to-date?

As of Jun 28, 2017, ICM has raised a total of $2B (USD).

How many employees does ICM have?

ICM has 750 employees as of Feb 4, 2024.

ICM - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Gene Therapy
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software